drugset

drugset / Trial / NCT04105231

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

NCT04105231 ↗

Phase 2 Active not recruiting 64 enrolled Lone Baandrup Copenhagen University Hospital, Denmark · collab Danish Center for Sleep Medicine · collab Glostrup University Hospital, Copenhagen · collab University of Copenhagen · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial examines the efficacy of cannabidiol (CBD) versus risperidone for treatment of psychosis in patients with non affective-psychosis and lifetime use of cannabis.

Timeline

Start: 2021-06-01
Primary completion: 2025-11-25
Completion: 2026-03-31

Publications

Rasmussen JO, Jennum P, Linnet K, Glenthoj BY, Baandrup L. Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial. BMC Psychiatry. 2021 Aug 14;21(1):404. doi: 10.1186/s12888-021-03395-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidiol	Other / unclassified	300 mg	Oral
Comparator	Risperidone	Other / unclassified	2 mg	Oral

Indications

No indication recorded.